Xenetic Biosciences Q1 2024 GAAP EPS $(0.78) Beats $(0.79) Estimate, Sales $510.817K Miss $650.000K Estimate

5/10/24 8:48:25 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XBIO alert in real time by email

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.79) by 1.27 percent. The company reported quarterly sales of $510.817 thousand which missed the analyst consensus estimate of $650.000 thousand by 21.41 percent. This is a 15.69 percent decrease over sales of $605.844 thousand the same period last year.

Get the next $XBIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XBIO

Date	Price Target	Rating	Analyst

More analyst ratings

$XBIO
Press Releases

Fastest customizable press release news feed in the world

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric ant
11/21/24 8:30:00 AM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or metastatic solid tumorsStrategic focus on exploratory investigator-initiated studies with institutional partnersEnded the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of
11/13/24 8:30:00 AM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with
11/12/24 9:00:00 AM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care

Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
5/22/24 5:00:00 PM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace
5/4/23 8:35:00 AM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range
5/3/23 8:35:00 AM ET
$XBIO
Biotechnology: Pharmaceutical Preparations
Health Care

Xenetic Biosciences Q1 2024 GAAP EPS $(0.78) Beats $(0.79) Estimate, Sales $510.817K Miss $650.000K Estimate

Chat with this insight

Recent Analyst Ratings for
$XBIO

$XBIO
SEC Filings

Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Xenetic Biosciences Inc.

Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

$XBIO
Press Releases

Fastest customizable press release news feed in the world

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

$XBIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Interim CEO and CFO Parslow James F

SEC Form 4 filed by Mizrahy Moshe

New insider Mizrahy Moshe claimed no ownership of stock in the company (SEC Form 3)

$XBIO
Financials

Live finance-specific insights

$XBIO
Leadership Updates

Live Leadership Updates

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

$XBIO
Market Insights

Live Market Insights